Biomarker Testing in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC)

Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread implementation of next-generation sequencing and reflex testing has significantly improved patient outcomes by enabling earlier identification of actionable alterations and more personalized, effective treatment strategies. Despite clear clinical benefits, biomarker testing remains underutilized due to barriers such as limited tissue availability, inconsistent testing workflows across institutions, reimbursement challenges, and delays in turnaround time. Overcoming these obstacles through standardized protocols, increased education, and broader access to comprehensive testing—remains essential to optimizing care for patients with metastatic NSCLC.